Quote:

---

In October 2021, the Company hired Alok Krishen, M.S., as Sr. Director, Head of Biostatistics, who has over 35 years of experience in biostatistics in the pharmaceutical industry.
*He most recently served as Director, Biostatistics at Parexel International. Before Parexel, he held positions of increasing responsibility for a combined 32 years at GlaxoSmithKline and Baxter Healthcare...
KOL @ GSK request to work on Cytodyn data/turn-around ?

---

That was the same month that Cytodyn filed suit against Amarex for messing up/messing around with the HIV BLA.

It's far more likely that the company hired a biostatistician to help with their suit in Oct. 2021 than as a helpful gesture from GSK -- so GSK could partner or buy CYDY three years later.

I appreciate you looking for connections, but sometimes it's worth stepping back to see if the breadcrumb trail we're following is composed largely of fallen leaves. History isn't solely composed of events that we can hook together to lead to a future we all want to see.

I think the hiring of Max Lataillade and the several scientific advisors that followed is a significant piece of information. It tells you that CYDY is not about to fall into a black hole, no matter how bad the sp is, and that's important in itself. There does seem to be a number of linkages with GSK, but what that means so far is pretty unclear. I'd be happy to see good results from the many trials that are ongoing or about to commence. Pumping up expectations doesn't help us when it's accomplished with hot air.